Research Article

Effect of Exogenous Fetuin-A on TGF-β/Smad Signaling in Hepatic Stellate Cells

Yulai Zhou,1 Shuang Yang,1 and Pan Zhang2

1Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China
2Department of Infectious Diseases, The Third Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan 410013, China

Correspondence should be addressed to Pan Zhang; zhangp2017@163.com

Received 21 July 2016; Revised 27 September 2016; Accepted 24 October 2016

Objective. To explore the effects of low concentration of exogenous fetuin-A intervention on TGF-β1 induced LX2 cells through detection of the expression of mRNA and protein of Smad2, Smad3, and Smad7.

Methods. MTT assay was used to detect the LX2 cells proliferation and the regression equation calculating software was applied to determine IC50 of fetuin-A. RT-PCR was used to determine the relative content of Smad2, Smad3, and Smad7 mRNA in LX2 cells. Western blot was used to detect the LX2 cells relative content of Smad2, Smad3, Smad7 protein expression, respectively.

Results. The analysis from RT-PCR and western blot showed that when compared with the other groups TGF-β1+fetuin-A group increased the expression of Smad2 and Smad3 while decreased the expression of Smad7 (P < 0.05).

Conclusion. Fetuin-A may improve the excessive activation of hepatic stellate cells which is caused by an enhanced positive regulation of Smad2 and Smad3 protein and the deficiency in negative regulation of Smad7 protein. This is through inhibiting the expression of Smad2 and Smad3 gene and promoting the expression of Smad7 gene. As a result, the development of liver fibrosis will be reduced.

1. Introduction

Fetuin-A, discovered in 1944, is a 59 kDa glycoprotein [1]. It is mainly synthesized by hepatic stellate cells (HSC) and thus closely related to liver. It works as a rare negative acute phase protein, downregulating the activity of macrophages, and has a strong anti-inflammatory effect [2]. Inflammation is one of the major factors that leads to liver fibrosis; thus anti-inflammatory effect of fetuin-A may influence the process of hepatic fibrosis. At the same time, fetuin-A is also known as a natural TGF-β antagonist [3] and is closely associated with TGF-β/Smad signaling pathway, which plays a key role in the process of liver fibrosis. Therefore, we inferred that fetuin-A may inhibit the process of liver fibrosis through TGF-β/Smad signaling pathway.

2. Materials and Methods

2.1. Materials

2.1.1. Cultivation of Human Hepatic Stellate (LX2) Cell Line.

Human hepatic stellate (LX2) cell lines were obtained from Xiangya central laboratory of Central South University. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), which is a modification of Basal Medium Eagle (BME), with a higher concentration of amino acids and vitamins than BME and additional supplemental components. It is also supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, and 100 µg/mL of streptomycin.

Conditions. The plates were cultured in a 5% CO2 and 100% humidity cell culture box.

Reagents. Trizol, Invitrogen, #15596-026; RevertAid™ H Minus First Strand cDNA Synthesis Kit, Fermentas #K1631; Deoxyribonuclease 1 (DNase I), Fermentas #EN0521 were used.

RiboLock™ Ribonuclease Inhibitor, Fermentas #EO0381; SYBR Green PCR Master Mix, ABI 4309155, were used.

First Antigen. Mouse Smad7 antibody (1:800), SANTA, SC-365846; rabbit TGFβ1 antibody (1:400), SANTA, SC-146; rabbit Smad2/3 antibody (1:400), CST, #3102; mouse fetuin-A
antibody (1:800), SANTA, SC-133146; mouse GAPDH antibody (1:800), SANTA, SC-365062, were used.

**Second Antigen.** Goat anti-mouse IgG/HRP (1:80000); goat anti-rabbit IgG/HRP (1:40000); goat anti-mouse IgG/HRP (1:80000); goat anti-rabbit IgG/HRP (1:40000); goat anti-mouse IgG/HRP (1:80000) were used.

### 2.1.2. Establishment of Four Experimental Groups

10% FCS + DMEM culture liquid

TGF-β1 experimental group: 10% FCS + DMEM culture liquid + final concentration of 5 ng/mL TGF-β1

TGF-β1 + fetuin-A experimental group: 10% FCS + DMEM culture liquid + final concentration of 5 ng/mL TGF-β1 + 10 ng/mL fetuin-A

TGF-β1 + asialoglycoprotein + fetuin-A experimental group: 10% FCS + DMEM culture liquid + final concentration of 5 ng/mL TGF-β1 + 10 ng/mL fetuin-A treated with asialoglycoprotein

### 2.2. Methods

#### 2.2.1. Determination of Fetuin-A Concentrations Intervention.

Cells were added in 96-well microtiter plates (100 μL/hole, approximately 1 × 10^4) and were cultured at 37°C in a 5% CO₂ humidified incubator for 24 hours which were then mixed with the appropriate concentration of tested compounds. The plates were cultured in a 5% CO₂ with the appropriate concentration of tested compounds. Each hole was added with 50 μL in MTT and incubated for 4 hours. Discard supernatant, and 150 μL DMSO was added to each hole to dissolve the armour and was shaken. The optical density of each hole at 570 nm. The temperature will remain the same during the whole process.

#### 2.2.2. RNA Isolation and Purification and Real-Time PCR.

Total RNA was extracted from cells using Trizol reagent with the instructions of Invitrogen. Reverse transcription was performed using RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer’s protocol. Real-time PCR samples were prepared with SYBR Green PCR Master Mix (ABI 4309155) and real-time PCR was performed with an ABI Prism 7500 Detector System. The Housekeeping Gene GADPH was used as an internal control. After SDS-PAGE, the proteins were transferred onto the PVDF membrane and hybridized with specific primary antibodies and were incubated with HRP-conjugated sheep anti-mouse IgG. Bands were viewed using the ECL kit (Amersham, Piscataway, NJ) according to the manufacturer’s instruction.

#### 2.2.3. Western Blot Analysis.

Western blot analysis was conducted according to previous studies [5, 6]. The cellular lysates extracted from the cells were used for protein assays. Protein concentration was detected by a spectrophotometer using a BCA protein assay kit. Equal amounts of protein were subjected to SDS-PAGE on a 10% poly-acrylamide gel and transferred to a polyvinylidene difluoride membrane (Millipore). The membrane with blotted protein was blocked for 1 hour at room temperature with blocking buffer containing 5% BSA, followed by incubation with antibodies overnight at 4°C. GAPDH was used as an internal control. After SDS-PAGE, the proteins were transferred onto the PVDF membrane and hybridized with specific primary antibodies and were incubated with HRP-conjugated sheep anti-mouse IgG. Bands were viewed using the ECL kit (Amersham, Piscataway, NJ) according to the manufacturer’s instruction.

#### 2.2.4. Statistical Analysis.

The data was presented as a mean ± SD. Using SPSS 15.0 software (SPSS, Chicago, IL), one-way analysis of variance (ANOVA) test was employed for the comparison among all groups. Levene’s test was then applied to compare the statistical difference between the two groups. Tamhane’s T2 test was used when the variance was unequal. All tests were two-sided and a P value < 0.05 was considered to be statistically significant. The comparison of means between groups was made up by ANOVA.

### 3. Results

#### 3.1. The Determination of the Interfering Concentration of Fetuin-A.

According to the results of MTT Assays (Figure 1), the concentration was set at fetuin-A 10 ng/mL.

#### 3.2. Real-Time PCR.

To monitor for endogenous fetuin-A retention and exogenous fetuin-A supplement, the RQ value of each group were measured. Statistical analysis (Figure 2) suggests that the gene transcription of Smad2 in samples in group C was lower than that of the samples in groups A, B, and D. Both groups A and D were negative control groups (P < 0.0001). The values of group C were significantly lower than group B sample (0.123 ± 0.202% versus 1.441 ± 2.70%). The analysis of Smad3 shows similar results, whereas the results for Smad7 were conversely represented. In summary, mRNA expressions of Smad2 and Smad3 in group C were decreased, while Smad7 was increased. The differences were all statistically significant.
Figure 1: Time-IC\textsubscript{50} of fetuin-A.

Figure 2: Relative expression of Smad2, Smad3, and Smad7. A: blank control group; B: TGF-\(\beta\)1 experimental group; C: TGF-\(\beta\)1 + fetuin-A experimental group; D: TGF-\(\beta\)1 + asialofetuin-A experimental group. The relative expression of Smad2, Smad3, and Smad7 was analyzed by RT-PCR. Experimental treatments were analyzed in triplicate. Data were represented as mean \(\pm\) SD. Statistics were analyzed with a one-way analysis of variance (ANOVA) test. Asterisk represents \(P < 0.05\).

3.3. Western Blot. To confirm well established functional consequence of exogenous fetuin-A, we analyzed differences in the translation of Smad2, Smad3, and Smad7 genes involved in TGF-\(\beta\)/Smad signaling pathway. The results of western blot (Figure 3) determine that mRNA translation of Smad2 and Smad3 in group C was significantly downregulated (0.662\(\pm\)2.03\% versus 1.404\(\pm\)3.36\%, 0.481\(\pm\)1.19\% versus 1.421 \(\pm\) 2.65\%), while Smad7 was significantly increased (1.522 \(\pm\) 4.53\% versus 0.677 \(\pm\) 1.23\%). The differences showed statistical significance. The housekeeping gene GADPH was
Figure 3: The protein abundance of Smad2, Smad3, and Smad7. (a) Representative bands showing the changes of Smad2, Smad3, Smad7, and GAPDH. Lane A: blank control group; Lane B: TGF-β1 experimental group; Lane C: TGF-β1 + fetuin-A experimental group; Lane D: TGF-β1+ asialofetuin-A experimental group. (b) Densitometric analysis of Smad2, Smad3, Smad7, and GAPDH. Relative protein expression was analyzed by western blot. Experimental treatments were analyzed in quadruplicate. The positive bands were quantitatively analyzed by Gel Pro 4.0 Analysis software after their integrated optical density (IOD) was measured. The housekeeping gene (GADPH) was used as an internal control. Data were represented as mean ± SD. Statistics were obtained with a one-way analysis of variance (ANOVA) test. Asterisk represents $P < 0.05$. 
used as an internal control and the differences between each experimental group were not statistically significant.

4. Discussion

Liver fibrosis is the excessive accumulation of extracellular matrix proteins, such as collagen. It is considered as a wound healing response to chronic liver injury. It always indicates the onset of progressive disease, which may eventually lead to cirrhosis and end-stage liver disease [7, 8]. HSC has a major role in the accumulation of extracellular matrix (ECM) which contributes to fibrogenesis. This is activated mainly through TGF-β/Smad pathway. Therefore, this experiment has attempted to explore how fetuin-A affects the gene expression of Smad2, Smad3, and Smad7, researching for how fetuin-A affects the pathway as well as its potential influence on HSC activation.

TGF-β works through multiple signaling pathways, affecting cell proliferation, apoptosis, recession, differentiation, and migration [9]. It is known as a major cytokine, with a complex function in HSC activation accelerating liver fibrosis [10, 11]. Its signaling pathways include Smad dependent and Smad independent pathways. Recent studies show that Smad proteins are important substrate for TGF-β receptor intracellular kinase. Furthermore, they effectively mediate the TGF-β in the intracellular signal transduction [12, 13].

The classical TGF-β/Smad pathway is a highly conserved linear cascade process. Firstly, TGF-β was combined with TGF-β type II receptor (TGFβRII) on cell membrane, providing it with kinase activity, and then combined with TGF-β receptor (TGFβRI). Activated TGFβRI is then combined with restriction Smad (R-Smad), phosphorylating the COOH end of Smad2 or Smad3. This formed R-S heteromeric transcription complexes with Smad4 which shifted towards the nucleus and bonded with sequence specific DNA. This complex plays a role in transcriptional regulation [14], mediating HSC transforming to fibroblast (myofibroblast, MFB) and leading to the development of fibrosis [15–18]. Smad7 gene is an inhibitor of TGF-β signaling pathway (inhibition Smad, I-Smad). Smad7 inhibits the phosphorylation of Smad2 and Smad3 through the activation of TGFβRI, while inhibiting Smad2 and Smad3 combination with receptors. This formed a negative feedback loop in TGF-β signaling and effectively antagonized fibrogenesis [19, 20]. On the other hand, I-Smad can enhance the interaction of E3 ubiquitin protein ligase, Smad ubiquitin regulatory factor 1/2 (Smurf1/2) and receptor complex, to regulate receptor update [21, 22].

When liver injury occurs, TGF-β enables HSC activation, proliferation, and differentiation into MFB, promoting collagen production. TGF-β mediates wound healing response through ALK/Smad2 and Smad3 signaling pathway [23]. The ongoing presence of the damaging factors alters the phenotypic conversion of HSC. As a result, the inhibition effect of Smad7 on the TGF-β negative feedback will be reduced. Consequently, HSC is excessively activated, causing the ECM metabolic imbalance. Eventually, the progression of liver fibrosis is deteriorated [24, 25]. Compared with the blank control group, the gene expression of Smad2 and Smad3 in the TGF-β1 experimental group was increased while Smad7 was decreased, indicating that TGF-β/Smad pathway may be involved in the process of excessive activation of HSC and hepatic fibrosis.

Fetuin-A is mainly synthesized and secreted by the liver. During the fetal period, the concentration of fetuin-A in serum is high and drops significantly after an inflammatory injury [26–28]. Fetuin-A is also a natural TGF-β antagonist [29], which can be applied in the TGF-β/Smad signaling pathway. Fetuin-A and TGFβRII have 18–19 amino acid sequence in common. Fetuin-A can be combined with TGF-β related cytokines such as bone morphogenetic proteins 2, 4, and 6 and TGF-β1 and TGF-β2, thus competitively blocking the combination of TGF-β and its TGFβRII on the cell surface. A study conducted by Carol confirmed that fetuin-A can inhibit the combination of TGF-β and its receptor and thus block the phosphorylation and nuclear translocation of Smad2 and Smad3 [30]. Judging from the close relationship between TGF-β/Smad signaling pathway and liver fibrosis, we can speculate that fetuin-A has the potential to affect the progression of liver fibrosis via the TGF-β/Smad signaling pathway.

MTT assay was used to detect the proliferation of LX2 cells. The half inhibitory concentration (IC50) of fetuin-A was then calculated by the regression equation software. The optimal concentration of fetuin-A was 10 ng/mL (Figure 1). At this concentration, the results of RT-PCR (Figure 2) and western blot (Figure 3) showed that, in comparison to the other groups, the gene expression of Smad2 and Smad3 in TGF-β1 + fetuin-A experimental group was enhanced while expression of Smad7 was suppressed. These differences were all statistically significant. Fetuin-A may reduce HSC hyperactivity and the severity of hepatic fibrosis. This is achieved by the suppression of Smad2 and Smad3 gene expression whereas the gene expression of Smad7 was promoted.

In conclusion, fetuin-A could be a protective agent for hepatic fibrogenesis through the TGF-β/Smad signaling pathway. Supplementation with exogenous fetuin-A could alter the balance between inflammation and liver fibrosis by reducing the inflammatory effect. Given that fetuin-A represents biological homology, a high affinity, and no significant side effects, the administration of fetuin-A confers protection against hepatic fibrosis. Therefore, further studies are required to explore the therapeutic potential of fetuin-A in the clinical management of acute liver failure.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

Yulai Zhou and Shuang Yang contributed equally to this work and share the first authorship.

Acknowledgments

This paper is supported by the Project supported by the Natural Science Foundation of Hunan Province, China (Grant No. 14JJ3043).
References

[1] K. O. Pedersen, "Fetuin, a new globulin isolated from serum," Nature, vol. 154, no. 3914, p. 575, 1944.

[2] H. Wang, W. Li, S. Zhu, P. Wang, and A. E. Sama, "Role of fetuin-A in injury and infection," in Acute Phase Proteins—Regulation and Functions of Acute Phase Proteins, F. Veas, Ed., chapter 15, pp. 625–633, InTech, Rijeka, Croatia, 2011.

[3] X.-H. Dai, P. Zhang, M.-F. Xiao et al., "Protective role of α2HS-glycoprotein in HBV-associated liver failure," International Journal of Molecular Sciences, vol. 12, no. 6, pp. 3846–3856, 2011.

[4] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method," Methods, vol. 25, no. 4, pp. 402–408, 2001.

[5] W. Ren, S. Chen, J. Yin et al., "Dietary arginine supplementation of mice alters the microbial population and activates intestinal innate immunity," The Journal of Nutrition, vol. 144, no. 6, pp. 988–995, 2014.

[6] W. Ren, J. Yin, M. Wu et al., "Serum amino acids profile and the beneficial effects of L-arginine or L-glutamine supplementation in dextran sulfate sodium colitis," PLoS ONE, vol. 9, no. 2, Article ID e88335, 2014.

[7] T. Koller, J. Kollerova, M. Huorka, I. Meciarova, and J. Payer, "Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients," European Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1108–1115, 2014.

[8] B. C. Fuchs, Y. Hoshida, T. Fuji et al., "Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma," Hepatology, vol. 59, no. 4, pp. 1577–1590, 2014.

[9] M. Wu, H. Xiao, G. Liu et al., "Glutamine promotes intestinal SlgA secretion through intestinal microbiota and IL-13," Molecular Nutrition & Food Research, vol. 60, no. 7, pp. 1637–1648, 2016.

[10] A. M. Gressner and R. Weiskirchen, "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets," Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 76–99, 2006.

[11] L. D. Presser, S. McRae, and G. Waris, "Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion," PLoS ONE, vol. 8, no. 2, Article ID e56367, 2013.

[12] Z.-Y. Ding, G.-N. Jin, H.-F. Liang et al., "Transforming growth factor β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling," Cellular Signalling, vol. 25, no. 10, pp. 1981–1992, 2013.

[13] K. Matsuoka, "Smad phospho-isofoms direct context-dependent TGF-β signaling," Cytokine and Growth Factor Reviews, vol. 24, no. 4, pp. 385–399, 2013.

[14] S.-K. Moon, W.-J. Kim, Y. H. Choi et al., "Mellitin inhibits TGF-β-induced pro-fibrotic gene expression through the suppression of the TGFBR1I-Smad, ERK1/2 and JNK-mediated signaling pathway," The American Journal of Chinese Medicine, vol. 42, no. 5, pp. 1139–1152, 2014.

[15] S. Dooley and P. Ten Dijke, "TGF-β in progression of liver disease," Cell and Tissue Research, vol. 347, no. 1, pp. 245–256, 2012.

[16] V. Paradis, D. Dargere, F. Bonvoust, M. Vidaud, P. Segarini, and P. Bedossa, "Effects and regulation of connective tissue growth factor on hepatic stellate cells," Laboratory Investigation, vol. 82, no. 6, pp. 767–774, 2002.

[17] J. Long, G. Wang, I. Matsuura, D. He, and F. Liu, "Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3)," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 99–104, 2004.

[18] K. Yoshida and K. Matsuoka, "Differential regulation of TGF-β1/Smad signaling in hepatic stellate cells between acute and chronic liver injuries," Frontiers in Physiology, vol. 3, article 53, 2012.

[19] M. J. Goumans and C. Mummery, "Functional analysis of the TGF β receptor/Smad pathway through gene ablation in mice," International Journal of Developmental Biology, vol. 44, no. 3, pp. 253–265, 2002.

[20] I. W. Taylor and J. L. Wrana, "Snapshot: the TGFβ pathway interactome," Cell, vol. 133, no. 2, pp. 378–378.e1, 2008.

[21] P. Kavask, R. K. Rasmussen, C. G. Causing et al., "Smad7 binds to Smurfl2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation," Molecular Cell, vol. 6, no. 6, pp. 1365–1375, 2000.

[22] S. Dooley, J. Hamzavi, K. Breitkopf et al., "Smad3 prevents activation of hepatic stellate cells and liver fibrosis in rats," Gastroenterology, vol. 125, no. 1, pp. 178–191, 2003.

[23] H. Seyhan, J. Hamzavi, E. Wiercinska et al., "Liver fibrogenesis due to cholestasis is associated with increased Smad3 expression and Smad3 signaling," Journal of Cellular and Molecular Medicine, vol. 10, no. 4, pp. 922–932, 2006.

[24] S. Dooley, M. Streckert, B. Delvoux, and A. M. Gressner, "Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts," Biochemical and Biophysical Research Communications, vol. 283, no. 3, pp. 554–562, 2001.

[25] S. Dooley, B. Delvoux, M. Streckert et al., "Transforming growth factor β signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts," FEBS Letters, vol. 502, no. 1-2, pp. 4–10, 2001.

[26] H. Wang and A. E. Sama, "Anti-inflammatory role of fetuin-A in injury and infection," Current Molecular Medicine, vol. 12, no. 5, pp. 625–633, 2012.

[27] W. Li, S. Zhu, J. Li et al., "A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation," PLoS ONE, vol. 6, no. 2, Article ID e16945, 2011.

[28] M. Sewerad, D. Liu, E. A. Partridge et al., "α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling," The Journal of Biological Chemistry, vol. 277, no. 22, pp. 19991–19997, 2002.

[29] M. Demetriou, C. Binkert, B. Sukhu, H. C. Tenenbaum, and J. W. Dennis, "Fetuin/α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist," Journal of Biological Chemistry, vol. 271, no. 22, pp. 12755–12761, 1996.

[30] C. J. Swallow, E. A. Partridge, J. C. Macmillan et al., "α2HS-glycoprotein, an antagonist of transforming growth factor β in vivo, inhibits intestinal tumor progression," Cancer Research, vol. 64, no. 18, pp. 6402–6409, 2004.